Discovery of 2‑(Imidazo[1,2‑b]pyridazin-2-yl)acetic Acid as a New Class of Ligands Selective
for the γ‑Hydroxybutyric Acid (GHB) High-Affinity Binding
Sites
posted on 2019-02-14, 00:00authored byJacob Krall, Francesco Bavo, Christina B. Falk-Petersen, Claus H. Jensen, Julie O. Nielsen, Yongsong Tian, Valeria Anglani, Kenneth T. Kongstad, Louise Piilgaard, Birgitte Nielsen, David E. Gloriam, Jan Kehler, Anders A. Jensen, Kasper Harpsøe, Petrine Wellendorph, Bente Frølund
Gabazine, a γ-aminobutyric
acid type A (GABAA)
receptor antagonist, has previously been reported to inhibit the binding
of [3H]NCS-382, a representative ligand of the high-affinity
binding site for the neuroactive substance γ-hydroxybutyric
acid (GHB). We herein report a study on the structural determinants
of gabazine for binding to (i) the orthosteric binding site of the
GABAA receptor and (ii) the high-affinity GHB binding site.
Expanding the structural diversity of available ligands for the high-affinity
GHB binding sites, this study identified 2-(imidazo[1,2-b]pyridazin-2-yl)acetic acid as a novel ligand-scaffold leading to
analogues with relatively high affinity (Ki 0.19–2.19 μM) and >50 times selectivity for the
[3H]NCS-382 over [3H]muscimol binding sites.
These
results highlight that gabazine interacts with the high-affinity GHB
and orthosteric GABAA receptor binding sites differently
and that distinct analogues can be generated to select between them.
To facilitate further in vivo studies, a promising prodrug candidate
for brain delivery was identified.